+ 33 1 46 99 68 20

Renewal of our mission-driven company status: a favorable opinion from the OTI (Independent Third-Party Organization)

Jul 2025

Between November 2024 and May 2025, Delbert Pharma was audited by Fideliance Audit, an independent COFRAC-accredited third-party body, as part of the renewal of its Mission driven company status, first obtained in 2023.

The purpose of this audit was to assess the practical implementation of our social and environmental commitments, as defined in our bylaws:

  1. Develop a favorable ecosystem for essential medicines and refuse any loss of opportunity for patients.
    2. Guarantee:
    well-being, balance and quality of life at work
    freedom to undertake ideas and actions
    – an environment of trust and respect.
    3. Integrate the collective challenge of environmental protection and contribute, alongside our partners, to reducing the ecological footprint of medicines.

Our raison d’être: Acting to maintain and develop medicines whose absence harms patients and the balance of healthcare systems – is thus implemented in a structured, measurable and monitored way.

At the end of the audit, the findings confirm:
Consistency between the company’s raison d’être and its activities
Effective implementation of the social and environmental objectives defined
Rigorous monitoring by the mission committee
Achievement of the results set at the end of the audit period.

This assessment confirms that our commitment to public health is not just an ambition, but a reality that is carried out every day by our employees.

Carbon Footprint of DELBERT Pharma

As a mission driven company, DELBERT Pharma has embedded in its mission the commitment to take concrete action in favor of accessible healthcare, while contributing to a more sustainable future. In line with this commitment, we conducted our first Carbon Footprint...

Delbert Pharma awarded Mission-driven company status

Paris, 09/27/2023 Delbert Pharma, a major player in the safeguarding and relocation of essential medicines, is proud to announce that it has officially been awarded Mission-driven company status in September 2023. This recognition, the fruit of intense collaborative...

New investment in Laboratoires Delbert

Vivalto Partners announces a significant investment in Laboratoires Delbert to support the company's development in the field of essential and orphan drugs. The historical investors - Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF...